Rankings / Longevity — Supplements
Yamanaka factors / partial reprogramming
Longevity · Epigenetic reprogramming
Tier D
High-risk evidence profile
Bottom line
Read Off Label grades Yamanaka factors / partial reprogramming as D (3.1/10) based on preclinical evidence, variable benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
Ocampo 2016 Cell and subsequent Belmonte work show rejuvenation of aged tissues in mice via cyclic OSK expression.
Studied, labeled, or reported-use context: No approved human protocol — Research only; not individualized guidance.
What the evidence says
Ocampo 2016 Cell and subsequent Belmonte work show rejuvenation of aged tissues in mice via cyclic OSK expression. Altos Labs ($3B+ funding) actively developing clinical protocols. No approved human therapy yet. A 2026 preclinical meta-analysis (14 studies) found epigenetic-clock (DNAmAge) reversal was NOT associated with functional improvement — a caution that "epigenomic rejuvenation" does not automatically mean restored function.
Mechanism
Transient expression of OCT4, SOX2, KLF4, MYC (or OSK without MYC) resets epigenetic age markers without inducing pluripotency; research-stage approach to reverse cellular aging
Studied, labeled, or reported dose & route
No approved human protocol
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Yamanaka factors / partial reprogramming's effects?
- Read Off Label rates the evidence for Yamanaka factors / partial reprogramming as Preclinical and the benefit magnitude as variable, producing an overall grade of D (3.1/10). Ocampo 2016 Cell and subsequent Belmonte work show rejuvenation of aged tissues in mice via cyclic OSK expression.
- What safety findings are reported for Yamanaka factors / partial reprogramming?
- Yamanaka factors / partial reprogramming has a med-high risk profile in the database. Med-High (cancer/teratoma risk; adventitial cell dedifferentiation) Legal status: Research only.
- What does the low Safety score for Yamanaka factors / partial reprogramming represent?
- The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Yamanaka factors / partial reprogramming?
- No approved human protocol This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Yamanaka factors / partial reprogramming work?
- Transient expression of OCT4, SOX2, KLF4, MYC (or OSK without MYC) resets epigenetic age markers without inducing pluripotency; research-stage approach to reverse cellular aging
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.